Remote monitoring guided by HeartLogic device alerts for heart failure patients
Compares device-alert remote follow-up with office visits in adults with heart failure.
Plain-language title generated from the registry record
Registry title: HeartLogic™ in Patients With Heart Failure.
Key facts
- Where
- Amiens, Brest, Caen, Grenoble, Lille, Marseille, Nantes, Paris, Poitiers, Rouen, Toulouse, and Tours, FranceSee the 15 sites
Where in France
- University Hospital of AmiensAmiens, FranceNot yet recruiting
- University Hospital of BrestBrest, FranceNot yet recruiting
- University Hospital of CaenCaen, FranceNot yet recruiting
- University hospital of GrenobleGrenoble, FranceNot yet recruiting
- University Hospital of LilleLille, FranceNot yet recruiting
- La Timone University HospitalMarseille, FranceNot yet recruiting
- Hopital du ConfluentNantes, FranceNot yet recruiting
- University Hospital of NantesNantes, FranceNot yet recruiting
- Georges-Pompidou European HospitalParis, FranceNot yet recruiting
- La Pitié SalpêtrièreParis, FranceNot yet recruiting
- University Hospital of PoitiersPoitiers, FranceTaking people
- University hospital of RouenRouen, FranceNot yet recruiting
- Pasteur clinicToulouse, FranceNot yet recruiting
- University Hospital of ToulouseToulouse, FranceNot yet recruiting
- University Hospital of ToursTours, FranceNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Poitiers University Hospital
- Trial code
- NCT07544771
- Record updated
- 19 October 2026
- Original description
This randomized, multicenter clinical trial will evaluate whether remote management guided by the HeartLogic™ algorithm improves outcomes compared with traditional face-to-face follow-up in adult patients with heart failure recently implanted with a HeartLogic™-enabled ICD or CRT-D device. The primary objective is to determine whether this strategy reduces, at 12 months, the proportion of patients with death, unscheduled hospitalization for heart failure, or deterioration in quality of life. Secondary objectives include assessment of hospitalization, mortality, quality of life, safety, and cost-effectiveness.Read full original descriptionShow less
HeartLogic™ Evaluation for Remote Monitoring vs. Office-based Follow-up in Patients With Heart Failure.
This randomized, multicenter clinical trial will evaluate whether remote management guided by the HeartLogic™ algorithm improves outcomes compared with traditional face-to-face follow-up in adult patients with heart failure recently implanted with a HeartLogic™-enabled ICD or CRT-D device. The primary objective is to determine whether this strategy reduces, at 12 months, the proportion of patients with death, unscheduled hospitalization for heart failure, or deterioration in quality of life. Secondary objectives include assessment of hospitalization, mortality, quality of life, safety, and cost-effectiveness.
Inclusion: Patients aged ≥18 years old; Patients implanted with a cardiac defibrillator for less than 6 months, with or without resynchronization, enabling the HeartLogic™ algorithm; Patients with a history of HF (left ventricular ejection fraction ≤40%; or at least one episode of clinical HF with NT-proBNP blood concentration ≥450 ng/L); Patients with New York Heart Association Class II or III HF; Patient able to comply with the protocol, including Latitude™ transmissions (including adequate connectivity), and study visits; Patients with compulsory health insurance.
Exclusion: Patients with a concomitant HF device other than cardiac resynchronization, such as a ventricular assist devices or cardiac contractility modulation devices; Participation to a concomitant study evaluating management of HF decompensation, or diuretic titration; Patients receiving State Medical Aid (Aide Médicale d'Etat); Patients on heart transplant list, or patients with a heart transplant; Patients not consenting and non-compliant with remote care directions; Patients with invasive remote HF monitoring device (such as CardioMems); Patients with a glomerular filtration rate <30 ml/min/m2; Patients enable to consent; Pregnant or breastfeeding women; Persons benefiting from a reinforced protection, namely minors, persons deprived of liberty by a judicial or administrative decision, adults under legal protection, and finally patients in emergency situations.